Purpose We conducted a multicenter real-world study in China to assess the association
between body mass index (BMI) and clinical outcomes in patients with atrial fibrillation (AF) …

This ARISTOPHANES analysis examined stroke/systemic embolism (SE) and major
bleeding (MB) among a subgroup of nonvalvular atrial fibrillation (NVAF) patients with …

Introduction oral anticoagulant (DOAC) agents are becoming the anticoagulation strategy of
choice for most clinical risks for which they are indicated. However, residual uncertainty …

Background: Atrial Fibrillation (AF) is the most common sustained cardiac arrhythmia.
Obesity is an independent risk factor for AF. Anticoagulants have been strongly …

Abstract Background Direct oral anticoagulants (DOACs) have been proven to be effective
and safe for prevention of ischemic stroke and systemic embolism in patients with non …

Large-scaled post-marketing surveillance studies (PMSSs) of 4 direct oral anticoagulants
(DOACs) for stroke prevention in non-valvular atrial fibrillation (AF) were conducted since …

Purpose Oral anticoagulants are crucial for preventing systemic thromboembolism in atrial
fibrillation (AF), with guidelines preferring non-vitamin K antagonist oral anticoagulants …

Background Because studies of direct oral anticoagulants in patients with venous
thromboembolism and non-valvular atrial fibrillation have had minimal representation of …

To our knowledge, this is the first NMA study comparing apixaban with rivaroxaban in
morbidly obese patients with AF. Our NMA showed there was no significant difference in …

Background The safety and effectiveness of reduced-dose apixaban 2.5 mg twice daily (BID)
have not been elucidated thoroughly in Japanese patients with nonvalvular atrial fibrillation …